Subunit-based mucosal vaccine delivery systems for pulmonary delivery - Are they feasible?

Abstract

Pulmonary infections are the most common cause of death globally. However, the development of mucosal vaccines that provide protective immunity against respiratory pathogens are limited. In contrast to needle-based vaccines, efficient vaccines that are delivered via noninvasive mucosal routes (such as via the lungs and nasal passage) produce both antigen-specific local mucosal IgA and systemic IgG protective antibodies. One major challenge in the development of pulmonary vaccines using subunit antigens however, is the production of optimal immune responses. Subunit vaccines therefore rely upon use of adjuvants to potentiate immune responses. While the lack of suitable mucosal adjuvants has hindered progress in the development of efficient pulmonary vaccines, particle-based systems can provide an alternative approach for the safe and efficient delivery of subunit vaccines. In particular, the rational engineering of particulate vaccines with optimal physicochemical characteristics can produce long-term protective immunity. These protect antigens against enzymatic degradation, target antigen presenting cells and initiate optimal humoral and cellular immunity. This review will discuss our current understanding of pulmonary immunology and developments in fabricating particle characteristics that may evoke potent and durable pulmonary immunity.

Keywords:

• Pulmonary
• vaccines
• subunit antigens
• particles
• nasal
• lungs
• adjuvants
• immunology

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

Dr Nirmal Marasini is supported by the University of Queensland Development fellowship and Dr Lisa Kaminskas is supported by National Health and Medical Research Council (NHMRC), career development fellowship